Why Patient Engagement Programs Lose Momentum

And how to find where it's happening before it shows up in your persistence data.

Most patient engagement programs don't fail at launch.

They lose momentum somewhere between month 3 and month 9 — and by the time persistence data confirms it, the damage is already done.

Strong enrollment. Successful first fill. Declining refills by month 6. By month 12, you're explaining persistence drops to your board with answers that don't satisfy anyone.

The pattern is consistent across pharma. Across therapy areas. Across company sizes.

So why does it happen — and how do you find it before it shows up in your numbers?

What does momentum loss actually look like?

It doesn't look like a failed program. It looks like a program that's still running.

Enrollment continues. Vendors still hit their SLAs. Dashboards still show strong activation metrics.

Every individual function appears to be working.

But underneath, patients are taking longer to refill. Coverage transitions go undetected. Side effect concerns surface in conversations that never reach your hub. Handoffs between vendors stretch quietly from days to weeks.

Momentum loss is invisible because each function is doing its job.

The problem lives between functions — and no function owns the space between.

What causes momentum loss in patient engagement?

The root causes are rarely about effort. They're about visibility.

Cross-functional fragmentation. Each team measures what they're accountable for. None measures what happens between teams.

Touchpoint optimization without continuity tracking. Programs are designed for activation moments, not sustained engagement.

Reactive infrastructure. Most patient engagement systems detect problems after they cause discontinuation — not before.

Misaligned definitions. What "patient engagement" means to Commercial is different from what it means to Medical Affairs or Patient Services. Without shared language, you can't measure shared outcomes.

These causes compound over time. By the time persistence drops are visible, the underlying patterns have been building for months.

How do you find momentum loss before it shows up in your data?

It requires what most pharma teams don't currently have: visibility, alignment, and measurement — across functions, anchored in their specific context.

Visibility into where patients move through your ecosystem, not just where they touch your vendors.

Alignment across Medical Affairs, Commercial, and Patient Services on what momentum loss actually means in your portfolio.

Measurement that captures not just whether interventions happened, but whether they worked.

These three elements aren't optional. They're the precondition for everything else.

When they come together, the gaps become visible. Not in theory — in the specific moments where your patients fall through.

What this requires

This work doesn't fit in any single vendor's offering.

It requires a structured approach designed for cross-functional teams to define momentum loss in their context and find where it's showing up — before persistence data confirms it.

This is the work we've been refining with senior leaders in pharma.

If your team is feeling the symptoms but can't quite see the pattern, send me a message.

— Liza, Linked Patient Learning